Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$0.39 - $0.71 $1,950 - $3,550
5,000 Added 8.55%
63,500 $26,000
Q4 2022

Feb 10, 2023

SELL
$0.33 - $10.44 $34,485 - $1.09 Million
-104,500 Reduced 64.11%
58,500 $23,000
Q3 2022

Nov 10, 2022

BUY
$0.92 - $11.16 $18,400 - $223,200
20,000 Added 13.99%
163,000 $139,000
Q2 2022

Aug 15, 2022

BUY
$1.02 - $1.83 $19,380 - $34,770
19,000 Added 15.32%
143,000 $166,000
Q1 2022

Oct 13, 2022

BUY
$1.06 - $2.1 $36,040 - $71,400
34,000 Added 37.78%
124,000 $175,000
Q1 2022

May 16, 2022

BUY
$1.06 - $2.1 $36,040 - $71,400
34,000 Added 37.78%
124,000 $175 Million
Q4 2021

Oct 13, 2022

BUY
$2.05 - $3.2 $127,099 - $198,400
62,000 Added 221.43%
90,000 $185,000
Q4 2021

Feb 15, 2022

BUY
$2.05 - $3.2 $178,349 - $278,400
87,000 Added 2900.0%
90,000 $185 Million
Q2 2021

Aug 12, 2021

SELL
$2.57 - $4.85 $64,249 - $121,249
-25,000 Reduced 89.29%
3,000 $12,000
Q4 2020

Oct 13, 2022

SELL
$1.15 - $2.4 $20,125 - $42,000
-17,500 Reduced 38.46%
28,000 $60,000
Q4 2020

Feb 09, 2021

SELL
$1.15 - $2.4 $20,125 - $42,000
-17,500 Reduced 38.46%
28,000 $59.6 Million
Q3 2020

Oct 13, 2022

SELL
$1.11 - $1.68 $108,225 - $163,800
-97,500 Reduced 68.18%
45,500 $55,000
Q3 2020

Nov 10, 2020

BUY
$1.11 - $1.68 $11,100 - $16,800
10,000 Added 28.17%
45,500 $55,000
Q2 2020

Aug 05, 2020

BUY
$1.69 - $4.2 $12,675 - $31,500
7,500 Added 26.79%
35,500 $61,000
Q1 2020

May 04, 2020

SELL
$1.26 - $3.38 $75,681 - $203,019
-60,065 Reduced 68.21%
28,000 $73,000
Q4 2019

Feb 05, 2020

BUY
$0.86 - $1.44 $75,735 - $126,813
88,065 New
88,065 $118,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $838M
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Samalin Investment Counsel, LLC Portfolio

Follow Samalin Investment Counsel, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samalin Investment Counsel, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samalin Investment Counsel, LLC with notifications on news.